Locally Advanced Pancreatic Ductal Adenocarcinoma Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Locally Advanced Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled2 locationsNCT07157033
Recruiting
Not Applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
British Columbia Cancer Agency200 enrolled1 locationNCT06574620
Recruiting
Phase 2

PULSAR in Systemic Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaOligometastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center47 enrolled1 locationNCT07269626
Recruiting

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
University of California, San Francisco70 enrolled1 locationNCT06600906
Recruiting
Not Applicable

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Fox Chase Cancer Center16 enrolled1 locationNCT06984562
Recruiting
Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04484909
Recruiting
Phase 2

A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Ductal Adenocarcinoma
West China Hospital23 enrolled1 locationNCT07101679